Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Spiroenone is a novel small molecule compound derived from Adlay (Coix lacryma-jobi), currently in preclinical development by Joben Bio Medical for the treatment of breast cancer. Joben Bio Medical, a Taiwanese biotechnology company specializing in botanical drug research, identified this specific spiroenone derivative through its R&D platform focused on plant-based extracts. While the exact molecular target has not been publicly disclosed, the compound has demonstrated anti-tumor activity relevant to breast cancer in early-stage studies. It is part of a broader effort by the company to develop pharmaceutical-grade botanical drugs from traditional medicinal plants, leveraging the bioactive components of Adlay seeds.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on spiroenone.